As expected, the European Commission approves Heron Therapeutics' (HRTX +0.9%) Zynrelef (formerly HTX-011), a fixed-dose combination of local anesthetic bupivacaine and nonsteroidal anti-inflammatory med meloxicam, for the treatment of postoperative pain from small-to-medium-sized surgical wounds in adults.
Two months ago, the advisory group CHMP adopted a positive opinion backing approval.
https://seekingalpha.com/news/3617651-herons-zynrelef-okd-in-europe-for-post-op-pain
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.